Compare SAH & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAH | LQDA |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.5B |
| IPO Year | 1997 | 2018 |
| Metric | SAH | LQDA |
|---|---|---|
| Price | $64.82 | $34.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $80.75 | $37.40 |
| AVG Volume (30 Days) | 207.1K | ★ 2.0M |
| Earning Date | 10-23-2025 | 11-03-2025 |
| Dividend Yield | ★ 2.34% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.73 | N/A |
| Revenue | ★ $15,178,100,000.00 | $69,216,000.00 |
| Revenue This Year | $7.85 | $904.79 |
| Revenue Next Year | $3.49 | $188.25 |
| P/E Ratio | $17.38 | ★ N/A |
| Revenue Growth | 9.09 | ★ 343.41 |
| 52 Week Low | $52.00 | $10.37 |
| 52 Week High | $89.62 | $34.02 |
| Indicator | SAH | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 52.18 | 70.78 |
| Support Level | $61.68 | $30.50 |
| Resistance Level | $65.79 | $32.80 |
| Average True Range (ATR) | 1.88 | 1.71 |
| MACD | 0.76 | 0.33 |
| Stochastic Oscillator | 82.46 | 99.85 |
Sonic Automotive is one of the largest auto dealership groups in the United States. The company has 108 franchised stores in 18 states, primarily in metropolitan areas in California, Texas, and the Southeast, plus 18 EchoPark used-vehicle stores, 16 collision centers, and 14 powersports locations. The franchise stores derive revenue from new and used vehicles plus parts and collision repair, finance, insurance, and wholesale auctions. Luxury and import dealerships make up about 86% of franchise new-vehicle revenue, while Honda, BMW, Mercedes, and Toyota constitute about 59% of new-vehicle revenue. BMW is the largest brand at about 25%. 2024's revenue was $14.2 billion, with Texas and California comprising 51% of the total. EchoPark's portion was $2.1 billion.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.